ArticleJournal of global health2025
Health risk assessment for severe COVID-19 in Taiwan: a multi-centre electronic health record study.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As the global battle against COVID-19 continues, understanding the factors contributing to severe outcomes remains critical for public health strategies. We aim to identify the determinants significantly influencing severe COVID-19 infection and mortality among the general population in Taiwan. Methods: We conducted a retrospective cohort study using data extracted from the Taipei Medical University Clinical Research Database from 1 January 2022 to 31 December 2022. We defined the primary outcomes as severe COVID-19 infection, including hospitalisation, ventilator use, intubation, and mortality. We performed logistic regression analyses to explore the association of various factors, including demographic characteristics, body mass index (BMI), Charlson Comorbidity Index score, and multiple comorbidities. Results: Among 96 489 confirmed COVID-19 cases, 44 996 (46.6%) were classified as high-risk patients. Compared to females, male patients had significantly higher risks of ventilator use (odds ratio (OR) = 1.245; 95% confidence interval (CI) = 1.147-1.352, P < 0.0001), intubation (OR = 1.115; 95% CI = 1.011-1.230, P = 0.03), and mortality (OR = 1.510; 95% CI = 1.332-1.713, P < 0.0001). Patients with lower BMI had significantly increased risks of ventilator use (OR = 0.972; 95% CI = 0.964-0.981, P < 0.0001) and mortality (OR = 0.92; 95% CI = 0.908-0.935, P < 0.0001), compared to patients with higher BMI. Patients with chronic comorbidities such as heart disease, moderate to severe kidney disease, diabetes, cancer, hypertension, anaemia, and Parkinson disease had significantly higher risks of severe COVID-19 or mortality compared to those without these conditions. Conversely, patients with peptic ulcer disease or hyperlipidaemia seem to have lower risks of severity and mortality compared to those without these conditions. Conclusions: We found that being male, having a lower BMI, and having certain chronic conditions increased the risk of severe COVID-19 outcomes, while peptic ulcer disease and hyperlipidaemia were linked to reduced risks. These findings highlight the need for targeted public health strategies for high-risk groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.